BMC Cancer

Table 4 Intracellular expression of chemokine ligands

From: Intracellular coexpression of CXC- and CC– chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation

Origin	Cell line	CXCL9		CXCL10		CXCL11		CXCL12		CCL19		CCL21		CCL27		CCL28
		%	MFI	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI
P	IPC-298	95.39	3.69	0.93	1.11	7.00	1.36	97.93	5.34	99.02	16.86	53.98	1.94	98.71	7.39	ns	ns
P	Mel-Juso	93.22	10.88	ns	ns	12.90	2.10	89.57	5.80	99.04	70.62	6.12	1.60	98.75	17.36	ns	ns
P	Mel-HO	96.59	8.39	7.32	1.32	65.87	5.83	97.86	8.12	98.62	60.07	82.62	3.72	98.65	23.48	ns	ns
P	IGR-39	14.05	1.52	ns	ns	10.49	1.37	95.86	3.89	98.76	16.71	23.50	1.54	98.58	5.21	ns	ns
P	WM-115	28.31	2.06	0.46	1.12	2.66	1.24	81.77	3.96	98.79	20.00	15.55	1.65	94.06	4.89	ns	ns
M	A-375	84.56	6.18	0.42	1.07	88.71	7.46	10.89	1.67	92.34	71.31	32.60	3.42	89.92	25.21	1.14	1.29
M	MeWo	45.53	5.28	1.46	1.44	46.10	8.72	24.41	2.15	50.06	34.71	23.62	3.96	37.85	10.86	1.74	1.86
M	SK-Mel28	67.63	3.06	2.01	1.18	82.59	5.72	71.82	3.09	86.62	44.41	28.42	1.96	86.34	14.37	ns	ns
M	Malme-3 M	50.32	3.45	ns	ns	71.62	3.45	77.48	3.37	98.02	34.57	5.45	1.70	97.90	11.06	ns	ns
M	SK-Mel 2	81.72	3.18	ns	ns	94.63	5.53	95.94	8.46	98.34	36.70	22.45	1.86	97.47	13.02	ns	ns
M	WM-266-4	71.84	4.57	15.19	1.74	46.26	3.24	98.24	9.56	98.58	30.17	60.21	3.71	98.50	11.38	1.14	1.25
M	IGR-37	87.92	5.06	ns	ns	36.32	1.88	92.76	3.78	98.83	47.66	38.71	2.44	98.96	21.35	ns	ns
M	Mel-RC08	49.96	3.29	ns	ns	80.84	6.87	16.64	1.68	86.38	55.25	22.94	2.19	82.77	15.33	1.56	1.22
P	Hut-78	1.90	1.69	ns	ns	ns	ns	ns	ns	65.99	11.71	ns	ns	39.11	3.81	ns	ns

For each cell line (Origin; P: primary tumor, M: metastasis) mean percentage (%) and mean fluorescence index (MFI; calculated as the ratio between the mean fluorescence of the samples stained with the mAb anti-receptor and their correspondent isotypic control) of cells which significantly expressed (p < 0.05) chemokine ligands intracellularly are shown (ns: not significant expression).

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com